Patents by Inventor James C. Samuelson
James C. Samuelson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11390862Abstract: Provided herein is a thermolabile proteinase and methods of using the same. In some embodiments, the thermolabile proteinase may comprise an amino acid sequence that is at least 90% identical to any of SEQ ID NOs:1-11 and at least one amino acid substitution in helix 3. The thermolabile proteinase is active at a temperature in the range of 4° C.-40° C. and is inactivated by raising the temperature to above 50° C., where the proteinase is substantially inactive at 65° C.Type: GrantFiled: December 21, 2020Date of Patent: July 19, 2022Assignee: New England Biolabs, Inc.Inventors: Minyong Chen, James C. Samuelson, Ming-Qun Xu, Aihua Zhang, Margaret Heider, Pingfang Liu
-
Publication number: 20210115427Abstract: Provided herein is a thermolabile proteinase and methods of using the same. In some embodiments, the thermolabile proteinase may comprise an amino acid sequence that is at least 90% identical to any of SEQ ID NOs:1-11 and at least one amino acid substitution in helix 3. The thermolabile proteinase is active at a temperature in the range of 4° C.-40° C. and is inactivated by raising the temperature to above 50° C., where the proteinase is substantially inactive at 65° C.Type: ApplicationFiled: December 21, 2020Publication date: April 22, 2021Applicant: New England Biolabs, Inc.Inventors: Minyong Chen, James C. Samuelson, Ming-Qun Xu, Aihua Zhang, Margaret Heider, Pingfang Liu
-
Publication number: 20200199565Abstract: Provided herein is a thermolabile proteinase and methods of using the same. In some embodiments, the thermolabile proteinase may comprise an amino acid sequence that is at least 90% identical to any of SEQ ID NOs:1-11 and at least one amino acid substitution in helix 3. The thermolabile proteinase is active at a temperature in the range of 4° C.-40° C. and is inactivated by raising the temperature to above 50° C., where the proteinase is substantially inactive at 65° C.Type: ApplicationFiled: December 18, 2019Publication date: June 25, 2020Applicant: New England Biolabs, Inc.Inventors: Minyong Chen, James C. Samuelson, Ming-Qun Xu, Aihua Zhang, Margaret Heider, Pingfang Liu
-
Patent number: 10633644Abstract: Provided herein is a thermolabile proteinase and methods of using the same. In some embodiments, the thermolabile proteinase may comprise an amino acid sequence that is at least 90% identical to any of SEQ ID NOs:1-11 and at least one amino acid substitution in helix 3. The thermolabile proteinase is active at a temperature in the range of 4° C.-40° C. and is inactivated by raising the temperature to above 50° C., where the proteinase is substantially inactive at 65° C.Type: GrantFiled: December 18, 2019Date of Patent: April 28, 2020Assignee: New England Biolabs, Inc.Inventors: Minyong Chen, James C. Samuelson, Ming-Qun Xu, Aihua Zhang, Margaret Heider, Pingfang Liu
-
Patent number: 10507233Abstract: Methods of capturing N-glycan linked glycomolecules including N-glycans, N-glycopeptides and N-glycoproteins are described. The methods provide substantially unbiased capture of charged and uncharged N-glycans and/or N-glycan linked glycomoleules. Binding reagents for substantially unbiased binding of N-glycans and/or N-glycan linked glycomolecules are also described.Type: GrantFiled: August 20, 2018Date of Patent: December 17, 2019Assignee: New England Biolabs, Inc.Inventors: Minyong Chen, Xiaofeng Shi, James C. Samuelson, Christopher H. Taron
-
Publication number: 20190008934Abstract: Methods of capturing N-glycan linked glycomolecules including N-glycans, N-glycopeptides and N-glycoproteins are described. The methods provide substantially unbiased capture of charged and uncharged N-glycans and/or N-glycan linked glycomoleules. Binding reagents for substantially unbiased binding of N-glycans and/or N-glycan linked glycomolecules are also described.Type: ApplicationFiled: August 20, 2018Publication date: January 10, 2019Applicant: New England Biolabs, Inc.Inventors: Minyong Chen, Xiaofeng Shi, James C. Samuelson, Christopher H. Taron
-
Patent number: 10080787Abstract: Methods of capturing N-glycan linked glycomolecules including N-glycans, N-glycopeptides and N-glycoproteins are described. The methods provide substantially unbiased capture of charged and uncharged N-glycans and/or N-glycan linked glycomolecules. Binding reagents for substantially unbiased binding of N-glycans and/or N-glycan linked glycomolecules are also described.Type: GrantFiled: June 26, 2015Date of Patent: September 25, 2018Assignee: New England Biolabs, Inc.Inventors: Minyong Chen, Xiaofeng Shi, James C. Samuelson, Christopher H. Taron
-
Publication number: 20170128554Abstract: Methods of capturing N-glycan linked glycomolecules including N-glycans, N-glycopeptides and N-glycoproteins are described. The methods provide substantially unbiased capture of charged and uncharged N-glycans and/or N-glycan linked glycomolecules. Binding reagents for substantially unbiased binding of N-glycans and/or N-glycan linked glycomolecules are also described.Type: ApplicationFiled: June 26, 2015Publication date: May 11, 2017Applicant: New England Biolabs, Inc.Inventors: Minyong Chen, Xiaofeng Shi, James C. Samuelson, Christopher H. Taron
-
Patent number: 8981067Abstract: Compositions relating to a combination of two types of separation matrix; and to variant host cells which contain at least one essential host protein that is fused to an affinity binding tag or has been mutated to replace at least two of a plurality of histidines or basic amino acids are provided. Methods are also provided that relate to isolating a recombinant protein from a lysate.Type: GrantFiled: August 26, 2011Date of Patent: March 17, 2015Assignee: New England Biolabs, Inc.Inventors: James C. Samuelson, Carine Robichon-Iyer, Jianying Luo
-
Publication number: 20150037866Abstract: Compositions relating to a combination of two types of separation matrix; and to variant host cells which contain at least one essential host protein that is fused to an affinity binding tag or has been mutated to replace at least two of a plurality of histidines or basic amino acids are provided. Methods are also provided that relate to isolating a recombinant protein from a lysate.Type: ApplicationFiled: August 26, 2011Publication date: February 5, 2015Applicant: NEW ENGLAND BIOLABS, INC.Inventors: James C. Samuelson, Carine Robichon-Iyer, Jianying Luo
-
Patent number: 8492117Abstract: Compositions and methods are provided for expression of a toxic protein in a host cell preferably a bacterial host cell where at least one T7 RNA polymerase gene Is contained on the host cell chromosome and one or more genes encoding a T7 RNA polymerase inhibitor is located on an F? plasmid or on the chromosome.Type: GrantFiled: December 3, 2007Date of Patent: July 23, 2013Assignee: New England Biolabs, Inc.Inventors: James C. Samuelson, Theodore B. Davis, Elisabeth A. Raleigh, Maurice W. Southworth
-
Publication number: 20110097737Abstract: Methods and compositions are provided for producing membrane proteins or toxic proteins from recombinant DNA introduced into a prokaryotic host cell by targeting the expressed proteins to the envelope of the host cell. The methods and compositions utilize a protein vehicle fused to a protein of interest. The fusion protein may contain one or more protease cleavage sites to separate the protein of interest from the protein vehicle either in vivo or in vitro. The protein vehicle is characterized by a membrane-tar peptide and a trans-membrane segment separated by a cytoplasmic amino acid sequence that includes a cytoplasmic affinity-binding domain.Type: ApplicationFiled: August 14, 2008Publication date: April 28, 2011Applicant: NEW ENGLAND BIOLABS, INC.Inventors: James C. Samuelson, Jianying Luo
-
Publication number: 20100129916Abstract: Compositions and methods are provided for expression of a toxic protein in a host cell preferably a bacterial host cell where at least one T7 RNA polymerase gene Is contained on the host cell chromosome and one or more genes encoding a T7 RNA polymerase inhibitor is located on an F? plasmid or on the chromosome.Type: ApplicationFiled: December 3, 2007Publication date: May 27, 2010Applicant: NEW ENGLAND BIOLABS ,INC.Inventors: James C. Samuelson, Theodore B. Davis, Elisabeth A. Raleigh, Maurice W. Southworth
-
Patent number: 7052897Abstract: Methods and compositions are provided for altering the DNA recognition and cleavage characteristics of an endonuclease without prior knowledge of the endonuclease's three-dimensional structure and/or amino acid residues responsible for activity and/or specificity. Methods include subjecting a mutagenized endonuclease gene library to a genetic selection in prokaryotic cells which tolerate the expression of mutated endonuclease and where the endonuclease is active and determining the altered recognition-site specificity for the endonuclease.Type: GrantFiled: January 9, 2003Date of Patent: May 30, 2006Assignee: New England BiolabsInventors: James C. Samuelson, Shuang-yong Xu